GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Abrocitinib tablets (Cibinqo, adults)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Cibinqo

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Keep renal, genotype, interaction and study-entry criteria separate

The new mirror summary retains the MDRD table and the distinct trial CrCl exclusion; current official confirmation was not obtained.

Before applying: Do not compound separate reduction rules or treat a trial-entry exclusion as an approved renal cutoff.

Evidence for this qualification

Selected-source qualification; independent clinician review pending.

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Abrocitinib tablets (Cibinqo, adults) - selected U.S. label sections

Product / population
Adult CIBINQO oral tablets. This entry does not supply a pediatric regimen.
Renal measure
MDRD eGFR; Table 1 reports mL/minute. Do not silently substitute Cockcroft-Gault CrCl.

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Renal starting dose - adults

Label eGFRStarting oral dose
60-89 mL/minute100 mg once daily
30-59 mL/minute50 mg once daily
15-29 mL/minuteNot recommended
Below 15 mL/minute, including renal replacement therapyNot recommended

For inadequate response in mild or moderate impairment, the label permits doubling the listed starting dose. Do not transfer that escalation to severe impairment.

Limits and renal-method distinction

This is a selected renal-dose summary, not the complete atopic-dermatitis treatment protocol. Review the full JAK-inhibitor boxed warnings, infection screening and interacting medicines before treatment.

Source revision: 6/2026 | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258

Scope: Local label summary; independent clinical review pending. Not a two-source validated protocol. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-specific interpretation

What the dialysis evidence actually supports

Removal information alone does not define a maintenance dose, supplemental dose or dialysis schedule. A reported regimen still requires its product, indication, renal measure and dialysis assumptions to match the patient.

GlobalRPh RX List - CIBINQO

Authored v5.9; retrieved 2026-09-10 - retained source, not freshly reviewed in this release

No dialysis regimen established in selected content

Read the source and its limits

These manual classifications apply only to the identified selected sections, not every retained source or the entire prescribing information. They are not dosing clearance.

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Abrocitinib tablets (Cibinqo, adults) - selected U.S. label sections

Adult CIBINQO oral tablets. This entry does not supply a pediatric regimen.

Renal method: MDRD eGFR; Table 1 reports mL/minute. Do not silently substitute Cockcroft-Gault CrCl.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - CIBINQO

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Do not multiply separate dose-reduction rules without product-specific support.

Dialysis evidence: No dialysis regimen established in selected content

CIBINQO abrocitinib, preserving the existing adult record; no age-eligibility expansion is inferred from this renal-only recheck.

Renal method: MDRD eGFR printed in mL/min; separate CrCl trial-entry limitation
Retrieved: 2026-09-10

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Keep renal, genotype, interaction and study-entry criteria separate

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

multiple adjustment scope

Keep renal, genotype, interaction and study-entry criteria separate

The new mirror summary retains the MDRD table and the distinct trial CrCl exclusion; current official confirmation was not obtained.

How to use this: Do not compound separate reduction rules or treat a trial-entry exclusion as an approved renal cutoff.

GlobalRPh RX List - CIBINQO

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAbrocitinib tablets (Cibinqo, adults) - selected U.S. label sectionsGlobalRPh RX List - CIBINQO
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258

Product and population scope

Adult CIBINQO oral tablets. This entry does not supply a pediatric regimen.

RDM32-abrocitinib-cibinqo-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Abrocitinib tablets (Cibinqo, adults) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult CIBINQO oral tablets. This entry does not supply a pediatric regimen.

Renal method: MDRD eGFR; Table 1 reports mL/minute. Do not silently substitute Cockcroft-Gault CrCl.
Source date: 6/2026
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Renal starting dose - adults

Label eGFRStarting oral dose
60-89 mL/minute100 mg once daily
30-59 mL/minute50 mg once daily
15-29 mL/minuteNot recommended
Below 15 mL/minute, including renal replacement therapyNot recommended

For inadequate response in mild or moderate impairment, the label permits doubling the listed starting dose. Do not transfer that escalation to severe impairment.

RDM32-abrocitinib-cibinqo-1 · Source locator: 2.3, Table 1; 8.6

Limits and renal-method distinction

This is a selected renal-dose summary, not the complete atopic-dermatitis treatment protocol. Review the full JAK-inhibitor boxed warnings, infection screening and interacting medicines before treatment.

RDM32-abrocitinib-cibinqo-2 · Source locator: Boxed warning; 2; 5; 7

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258
Retrieved
2026-09-05
DailyMed Set ID
3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258
Label revision
6/2026
Renal-function method
MDRD eGFR; Table 1 reports mL/minute. Do not silently substitute Cockcroft-Gault CrCl.
Source date/version
6/2026
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
ff6334a4aab7fb942e5d98a19e7709c2fb7c2cd55c543c51c72788a05126aa47
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - CIBINQO

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · CIBINQO abrocitinib, preserving the existing adult record; no age-eligibility expansion is inferred from this renal-only recheck.

Renal method: MDRD eGFR printed in mL/min; separate CrCl trial-entry limitation
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-10

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Before using this finding

Do not multiply separate dose-reduction rules without product-specific support.

Dialysis evidence: No dialysis regimen established in selected content

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The retrieved table specifies 100 mg once daily for mild impairment (MDRD eGFR 60-89, printed mL/min) and 50 mg once daily for moderate impairment (30-59); it allows doubling the initial dose for inadequate response in those groups. Severe impairment (15-29) and ESRD, including renal replacement therapy, are not recommended.

The selected source reports no renal-replacement study and notes that phase 3 atopic-dermatitis trials excluded baseline CrCl below 40 mL/min. MDRD units, trial-entry CrCl and CYP2C19-related changes are separate issues. This pass did not obtain a fresh exact official label; no combined renal/genotype/interaction algorithm is supplied.

RDM59-rxlist-abrocitinib-cibinqo-ac2f1b5ad3-C1 · Source locator: Dosage: Renal Impairment Table 1; Use in Specific Populations; renal PK

Source-specific limits

Selected named sections only; not a complete monograph or independent clinical approval.

A label mirror is not independent corroboration of its underlying label. Fresh official confirmation is pending unless a separate official card is shown.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/cibinqo-drug/
Retrieved
2026-09-10
Renal-function method
MDRD eGFR printed in mL/min; separate CrCl trial-entry limitation
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
34d7982508037b3d55abb117d3fa4f4a53f9ad3d424fa541cab979f6f3be4296

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f6d6fcd-e9f9-42c8-bfa2-bb2cfc9ed258
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
34ed9ac041655a121945e78e9535dbe5168b1aa9e9e83f2d68d90bd119e6dc9c
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report